MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

22/10/2024 - 19:30

ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)-- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced today that they have entered into an agreement in which TerSera will acquire global rights to MARGENZA® (margetuximab-cmkb).
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA® | MGNX Stock News